Grifols Faces Closure Calls in Canada After Two Donor Deaths

Edgen Stock

·Mar 30 2026, 21:50

Partager sur

Partager sur

Copier le lien

Key Takeaways

Canadian health advocates are demanding the closure of all Grifols plasma facilities following two deaths and a lawsuit linked to the company's Winnipeg operations. The call for a ban intensified after Health Canada reported compliance issues at four other Grifols sites, signaling significant legal and operational risks for the multinational.

Public health proponents are calling for the closure of Grifols facilities across Canada after two plasma donors died in Winnipeg.
The company also faces a lawsuit for kidney damage from a third individual and separate non-compliance reports from Health Canada at four sites.
These events create significant reputational and financial risk for Grifols, potentially leading to forced closures and wider regulatory scrutiny of the private plasma industry.

Advocates Demand Closures After Two Donor Deaths

On March 30, 2026, public health advocates across Canada called for the immediate closure of plasma collection facilities operated by the multinational firm Grifols. The demand follows two deaths in Winnipeg of individuals who had sold their plasma to the company. The incidents have placed intense scrutiny on the safety and ethics of the for-profit plasma industry in the country. In addition to the fatalities, a third person is suing Grifols, alleging the company is responsible for kidney damage sustained from a plasma sale. This cluster of severe adverse events presents a direct challenge to Grifols' social license to operate and raises the prospect of significant legal liabilities.

Health Canada Cites Non-Compliance at Four Additional Sites

The crisis for Grifols extends beyond the events in Winnipeg. Health Canada has separately reported instances of non-compliance at four other Grifols collection sites, amplifying concerns about systemic operational failures. For investors, these regulatory flags, combined with the deaths and lawsuit, represent a material threat. The situation could force the permanent closure of its Canadian operations, damage the company's global reputation, and trigger a broader, more stringent regulatory framework for the entire private plasma collection sector. The financial fallout could include substantial legal costs, loss of revenue from its Canadian footprint, and a decline in investor confidence.